Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640759 | 0.91 | LMNA (0.59) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL516209 | 0.90 | NPC1 (0.50) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL2360618 | 0.90 | NPC1 (0.65) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL2640808 | 0.84 | MAPT (0.52) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL516913 | 0.82 | MAPT (0.53) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL516677 | 0.82 | MAPT (0.46) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL2640833 | 0.81 | MAPT (0.45) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL2640845 | 0.81 | MAPT (0.49) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL12185175 | 0.80 | MAPT (0.42) | NPC1RAB9AALDH1A1MAPTTP53 | |
| SCHEMBL516813 | 0.80 | ALOX5AP (0.48) | NPC1RAB9AALDH1A1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356113-B1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER IP GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-2569309-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| WO-2011141325-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141325-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010054764-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054762-A1 | AMINOALKYL-SUBSTITUTED COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054763-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2008141731-A2 | INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE AG (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | NPC1 1261/4885RAB9A 4372/4885ALDH1A1 604/4885 |
| US-20110312930-A1 | Aryl compounds with aminoalkyl substituents and their use | VHL, HIF1AN, HIF1A | NPC1 773/4885RAB9A 3733/4885ALDH1A1 297/4885 |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | FLT4, VEGFA, MKI67 | NPC1 1028/4885RAB9A 1563/4885ALDH1A1 1552/4885 |
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | NPC1 1242/4885RAB9A 3911/4885ALDH1A1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.